Avadel Pharmaceuticals sought FDA approval for new indications and secured an exclusive licensing deal with XWPharma.
1 report, 1 independent
Updated Sep 4
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Avadel Pharmaceuticals sought FDA approval for new indications and secured an exclusive licensing deal with XWPharma.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Avadel Pharmaceuticals secured an exclusive global license agreement with XWPharma for the development of valiloxybate.Sub-event
Avadel secured an exclusive licensing deal with XWPharma while seeking FDA approval.1 source
Keep exploring
The entities involved
-
Avadel Pharmaceuticals
specialty pharmaceutical company
Nothing else this week.
- FDA
-
XWPHARMA
Nothing else this week.
Related events
- Generic medicine services are seeking approval for launch from the FDA.
- New FDA rule threatens the ability to import medicines.
- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
- Argenx SE announced it is listed on Nasdaq and is seeking FDA priority review and approval.
- Policymakers are considering ways to influence the drug market, including potential changes to patent rights and the FDA approval process.
Coverage
Newest first; wire copies grouped- Pharmaceutical TechnologyAvadel secures rights to develop valiloxybate globally Avadel Pharmaceuticals has signed an exclusive worldwide licensing deal with XWPharma for the development and commercialisation of valiloxybate,